Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials

医学 银屑病 斑块性银屑病 安慰剂 银屑病面积及严重程度指数 不利影响 皮肤科生活质量指数 体表面积 随机对照试验 皮肤病科 生活质量(医疗保健) 疾病严重程度 内科学 临床试验 外科 年轻人 物理疗法 意向治疗分析 临床研究阶段 置信区间 皮肤损伤 胃肠病学 体质指数
作者
Linda Stein Gold,April W. Armstrong,Jennifer Soung,Ronald B. Vender,Álvaro González-Cantero,Matthias Hoffmann,Scott Guenthner,Chih-ho Hong,Dedee Frances Murrell,Eingun James Song,Leon Kircik,Matthias Augustin,Maxwell B. Sauder,Sascha Gerdes,Ofelia Reyes Servín,Bassey Effiom Edem,Jennifer Campbell,Kellen G. Cresswell,Lea Kephart,Shu Li
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:195 (4): 600-600 被引量:4
标识
DOI:10.1093/bjd/ljag264
摘要

BACKGROUND: Icotrokinra, a targeted oral peptide, precisely blocks the interleukin-23 receptor. In two phase III moderate-to--severe plaque psoriasis trials, ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604), icotrokinra provided significantly higher skin clearance rates vs. placebo at week 16 and deucravacitinib at weeks 16 and 24. OBJECTIVES: To evaluate the clinician- and patient-reported outcomes (PROs) for participants who received icotrokinra in the ICONIC-ADVANCE 1 and ADVANCE 2 phase III clinical trials. METHODS: ICONIC-ADVANCE 1 and 2 randomized (2 : 1 : 2 and 4 : 1 : 4, respectively) adults with moderate-to-severe plaque psoriasis to icotrokinra 200 mg, placebo (transition to icotrokinra at week 16) or deucravacitinib 6 mg once daily (transition to icotrokinra at week 24). Outcomes assessed through week 52 included proportions of participants achieving Investigator Global Assessment (IGA) 0/1 (with ≥ 2-grade improvement from baseline), Psoriasis Area and Severity Index (PASI) 90, IGA 0, PASI 100, scalp-specific IGA (ss-IGA) 0/1, several well-established PROs, and adverse events (AEs). RESULTS: ICONIC-ADVANCE 1 and 2 randomized 1505 participants (774 and 731, respectively). Skin clearance rates among participants randomized to icotrokinra increased through week 24 and were durable through week 52, with approximately 70-75% exhibiting clear/almost clear skin (IGA 0/1, PASI 90) and approximately 50% demonstrating completely clear skin (IGA 0, PASI 100) during weeks 24-52. Among participants achieving clear/almost clear skin at week 16, around 85-90% maintained response at week 52. Response rates for ss-IGA 0/1 and PROs were also durable through week 52. Participants who transitioned from placebo or deucravacitinib to icotrokinra exhibited increasing response rates that were comparable to participants randomized to icotrokinra through week 52. The AE profile was similar to placebo through week 16 and showed lower AE rates than deucravacitinib through week 24; no safety signals were observed through week 52. CONCLUSIONS: Once-daily icotrokinra provided robust, durable skin clearance and symptom improvement, with no safety signals, through week 52 in adults with moderate-to-severe plaque psoriasis. Participants transitioning from placebo or deucravacitinib to icotrokinra achieved similar increased response rates to participants who were randomized to icotrokinra through week 52. Our findings support icotrokinra as a systemic therapy with long-term robust disease control and a favourable safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
丘比特的应助被randong采纳,获得10
刚刚
刚刚
saturn发布了新的文献求助10
1秒前
1秒前
里打动完成签到,获得积分10
2秒前
Yaya发布了新的文献求助10
2秒前
oddar发布了新的文献求助20
2秒前
阳光绿柏完成签到,获得积分10
3秒前
彭于晏的应助被权瑞松采纳,获得30
3秒前
orixero的应助被lei采纳,获得10
3秒前
Scarlett2完成签到,获得积分10
4秒前
4秒前
Nole的应助被忧郁鸿煊采纳,获得30
5秒前
Liucky发布了新的文献求助10
5秒前
卢小妹发布了新的文献求助10
5秒前
5秒前
思川发布了新的文献求助10
5秒前
6秒前
小鱼发布了新的文献求助10
6秒前
传奇3的应助被标致老三采纳,获得10
7秒前
qingniujushi发布了新的文献求助10
8秒前
墨鱼完成签到,获得积分10
8秒前
顺心秋凌发布了新的文献求助10
9秒前
吴123发布了新的文献求助10
10秒前
11完成签到,获得积分10
10秒前
zhuwei完成签到,获得积分10
10秒前
10秒前
光明磊落发布了新的文献求助10
10秒前
顺利大门完成签到,获得积分10
11秒前
852的应助被LingYue采纳,获得10
11秒前
11秒前
小马甲的应助被tt采纳,获得10
12秒前
万能图书馆的应助被xhsz1111采纳,获得10
12秒前
天空之城美完成签到,获得积分10
14秒前
15秒前
111发布了新的文献求助10
15秒前
ding完成签到,获得积分10
15秒前
Yv发布了新的文献求助10
15秒前
lx的应助被拼搏的绿凝采纳,获得10
16秒前
CipherSage的应助被无限的烧鹅采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193361
求助须知:如何正确求助?哪些是违规求助? 9579602
关于积分的说明 21866201
捐赠科研通 7792983
什么是DOI,文献DOI怎么找? 3437263
关于科研通互助平台的介绍 2560718
邀请新用户注册赠送积分活动 2484082